Related Experiment Video
Updated: Jun 24, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
PPIH acts as a potential predictive biomarker for patients with common solid tumors
Jun Ye1, Jianchao Ying2, Haixia Chen3
1Department of Clinical Laboratory, The Second Affiliated Hospital of Guizhou Medical University, Kaili, Guizhou, 556000, China.
BMC Cancer
|June 4, 2024
Summary
PPIH protein is elevated in liver, colon, and breast cancers, indicating a worse prognosis. However, decreased serum PPIH levels show potential as a novel diagnostic biomarker for these solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Previous studies identified PPIH upregulation in Hepatocellular Carcinoma (LIHC).
- The role of PPIH in other solid tumors and as a serum marker remained unexplored.
Purpose of the Study:
- Investigate PPIH expression and its prognostic implications across various solid tumors.
- Evaluate PPIH as a potential serum tumor marker for early cancer detection.
Main Methods:
- Utilized bioinformatics analysis and clinical sample evaluation for PPIH expression.
- Assessed PPIH's association with overall survival using TCGA data.
- Integrated serological studies to evaluate PPIH as a serum marker.
Main Results:
- PPIH mRNA levels significantly differed in multiple tumors compared to normal tissues.
- Elevated PPIH mRNA and protein in LIHC, Colon Adenocarcinoma (COAD), and Breast Cancer (BC) correlated with poorer prognosis.
- Decreased serum PPIH levels observed in LIHC, COAD, BC, and gastric cancer patients, enhancing diagnostic accuracy when combined with existing markers.
Conclusions:
- PPIH shows potential as a predictive biomarker for cancer patients.
- Secreted PPIH in serum may serve as a novel diagnostic marker for solid tumors.
